Food and Drug Administration has approved an investigational new drug application for a clinical trial to evaluate CBD as an adjunctive method to treat opioid use disorder. The FDA’s approval for the clinical trial evaluating Nantheia ATL5, an investigational drug using CBD as an adjunctive treatment for opioid use disorder. Nantheia ATL5 is an oral product with 100mg of CBD per soft gel capsule utilizing Liquid Structure technology, licensed from the Israeli pharmaceutical company Lyotropic Delivery Systems, which enhances the effectiveness and stability of CBD. What do you think about the use of CBD to treat Opioid Addiction ?

Previous Article

Microbes used in Food Making

Next Article

Adding Suspicious Files on Google Drive